Hepatitis C treatment side-effects: latest news

Hepatitis C treatment side-effects resources

  • Side-effects of hepatitis C treatment

    Interferon and ribavirin can cause difficult side-effects. These can be severe, though they will differ in severity from person to person and can lessen as treatment goes on....

    From: Booklets

    Information level Level 2
  • Hepatitis C treatment

    Deciding on the best time to take treatment for hepatitis C is not straightforward.It’s important to get support and advice to help you with this...

    From: The basics

    Information level Level 1

Hepatitis C treatment side-effects features

Hepatitis C treatment side-effects in your own words

Hepatitis C treatment side-effects news from aidsmap

More news

Hepatitis C treatment side-effects news selected from other sources

  • Optimism About HCV Treatment Comes With Caveats

    Despite significant advances in treatment for individuals with HCV infection, several important issues prevail in this patient population.

    22 March 2017 | Medscape
  • Are New Drugs for Hepatitis C Safe? A Report Raises Concerns

    Drugs approved in recent years that can cure hepatitis C may have severe side effects, including liver failure, a new report suggests. The number of adverse events appears relatively small, and the findings are not conclusive. But experts said the report was a warning that should not be ignored.

    25 January 2017 | New York Times
  • HCV Drugs May Reactivate HBV, FDA Warns

    Patients with a past or current hepatitis B virus (HBV) infection can experience sometimes fatal HBV reactivation if they take any of nine direct-acting antivirals for hepatitis virus C (HCV) infection, the US Food and Drug Administration (FDA) announced today.

    06 October 2016 | Medscape (free registration required)
  • Adding ribavirin to Harvoni for hepatitis C increases side effects but not efficacy

    Combining sofosbuvir/ledipasvir (Harvoni) with ribavirin was associated with a greater likelihood of adverse events and laboratory abnormalities, but did not significantly increase the chances of sustained response for genotype 1 chronic hepatitis patients compared to sofosbuvir/ledipasvir alone.

    29 June 2015 | HIVandHepatitis.com
  • Interferon-free therapy alters lipid metabolism, glucose homeostasis in chronic HCV patients

    Patients with chronic hepatitis C treated with an interferon-free regimen consisting of sofosbuvir and ribavirin experienced changes in LDL, triglycerides, hemoglobin A1C and metabolic and hepatic lipid gene expression in a study presented at ID Week 2013.

    14 October 2013 | Healio Hepatology
  • Depression in HCV Often Resolves After Interferon Treatment

    Depression affects up to 50% of patients with chronic hepatitis C virus (HCV) infection receiving treatment with interferon, but it appears to be self-limiting and does not usually require antidepressant therapy, new research suggests.

    12 April 2013 | Medscape (requires registration)
  • Health Canada Warns Of Serious Skin Reactions From Hepatitis C Drug

    Two months after the FDA issued a safety alert informing about the serious skin reactions, some fatal, in patients taking Vertex Pharmaceuticals Inc.'s (VRTX: Quote) hepatitis C drug Incivek (telaprevir), it is now health Canada's turn to alert health-care providers and patients.

    01 March 2013 | RTT News
  • Hepatitis C Model Delivers Great Care Anywhere

    Optimal HCV treatment for patients in a comprehensive health system requires an efficient and effective process. Ideally, the established structure would support rural as well as urban settings and allow for sharing of information, education of providers, and metrics to monitor treatments. Such a process was established successfully within the Department of VA.

    25 February 2013 | Infectious Disease Special Edition
  • Copy of Drug interaction warning for hepatitis C: serious side effects when using telaprevir and bosentan

    A medical team in Paris, France, has reported an unexpected and disturbing drug interaction between a drug used to treat pulmonary arterial hypertension—bosentan (Tracleer)—and the HCV drug telaprevir. The interaction led to serious side effects.

    15 February 2013 | CATIE
  • Drug interaction warning for hepatitis C: serious side effects when using telaprevir and bosentan

    A medical team in Paris, France, has reported an unexpected and disturbing drug interaction between a drug used to treat pulmonary arterial hypertension—bosentan (Tracleer)—and the HCV drug telaprevir. The interaction led to serious side effects.

    15 February 2013 | CATIE
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.